AU647484B2 - Composition and method for topical treatment of damaged or diseased tissue - Google Patents

Composition and method for topical treatment of damaged or diseased tissue

Info

Publication number: AU647484B2
Authority: AU; Australia
Prior art keywords: composition; molecular weight; daltons; heparin; copolymer
Prior art date: 1990-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU78692/91A

Other languages

English (en)

Other versions

AU7869291A (en

Inventor

R. Martin Emanuele

Robert L. Hunter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LadRx Corp

Original Assignee

CytRx Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-26

Filing date

1991-04-25

Publication date

1994-03-24

1991-04-25 Application filed by CytRx Corp filed Critical CytRx Corp

1991-11-11 Publication of AU7869291A publication Critical patent/AU7869291A/en

1994-03-24 Application granted granted Critical

1994-03-24 Publication of AU647484B2 publication Critical patent/AU647484B2/en

2011-04-25 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 95
238000000034 method Methods 0.000 title claims description 44
230000000699 topical effect Effects 0.000 title description 15
229920002683 Glycosaminoglycan Polymers 0.000 claims description 62
239000002253 acid Substances 0.000 claims description 54
229920001577 copolymer Polymers 0.000 claims description 48
229920000669 heparin Polymers 0.000 claims description 45
229960002897 heparin Drugs 0.000 claims description 45
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 44
229920001400 block copolymer Polymers 0.000 claims description 25
229920000045 Dermatan sulfate Polymers 0.000 claims description 22
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 17
229940051593 dermatan sulfate Drugs 0.000 claims description 17
241001465754 Metazoa Species 0.000 claims description 16
239000004599 antimicrobial Substances 0.000 claims description 14
150000001875 compounds Chemical class 0.000 claims description 14
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 12
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 7
239000000243 solution Substances 0.000 claims description 7
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
229920002971 Heparan sulfate Polymers 0.000 claims description 6
230000014508 negative regulation of coagulation Effects 0.000 claims description 6
229940121375 antifungal agent Drugs 0.000 claims description 5
229920002674 hyaluronan Polymers 0.000 claims description 5
229960003160 hyaluronic acid Drugs 0.000 claims description 5
125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 claims description 5
230000003444 anaesthetic effect Effects 0.000 claims description 4
239000002260 anti-inflammatory agent Substances 0.000 claims description 4
229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
229920001499 Heparinoid Polymers 0.000 claims description 3
239000003102 growth factor Substances 0.000 claims description 3
239000002554 heparinoid Substances 0.000 claims description 3
229940025770 heparinoids Drugs 0.000 claims description 3
229940043138 pentosan polysulfate Drugs 0.000 claims description 3
229940127215 low-molecular weight heparin Drugs 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 claims 3
230000000843 anti-fungal effect Effects 0.000 claims 3
239000003055 low molecular weight heparin Substances 0.000 claims 1
239000000499 gel Substances 0.000 description 55
210000001519 tissue Anatomy 0.000 description 54
208000027418 Wounds and injury Diseases 0.000 description 20
206010052428 Wound Diseases 0.000 description 16
230000006378 damage Effects 0.000 description 16
210000003491 skin Anatomy 0.000 description 16
206010015150 Erythema Diseases 0.000 description 12
230000000694 effects Effects 0.000 description 12
231100000321 erythema Toxicity 0.000 description 12
239000004615 ingredient Substances 0.000 description 12
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 11
-1 antibody Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 10
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
208000014674 injury Diseases 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
210000002615 epidermis Anatomy 0.000 description 8
230000035876 healing Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 6
125000000129 anionic group Chemical group 0.000 description 6
150000002016 disaccharides Chemical group 0.000 description 6
239000002674 ointment Substances 0.000 description 6
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
239000012530 fluid Substances 0.000 description 5
229920001983 poloxamer Polymers 0.000 description 5
229920001992 poloxamer 407 Polymers 0.000 description 5
229940044476 poloxamer 407 Drugs 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 4
235000004866 D-panthenol Nutrition 0.000 description 4
239000011703 D-panthenol Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
229960000458 allantoin Drugs 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
208000002352 blister Diseases 0.000 description 4
239000006071 cream Substances 0.000 description 4
210000004207 dermis Anatomy 0.000 description 4
229960003949 dexpanthenol Drugs 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
229960000502 poloxamer Drugs 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
229910052709 silver Inorganic materials 0.000 description 4
239000004332 silver Substances 0.000 description 4
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000008733 trauma Effects 0.000 description 4
229920001287 Chondroitin sulfate Polymers 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000016611 Proteoglycans Human genes 0.000 description 3
108010067787 Proteoglycans Proteins 0.000 description 3
239000002250 absorbent Substances 0.000 description 3
230000002745 absorbent Effects 0.000 description 3
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
244000005700 microbiome Species 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000005855 radiation Effects 0.000 description 3
150000003378 silver Chemical class 0.000 description 3
238000005507 spraying Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
208000037816 tissue injury Diseases 0.000 description 3
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
206010006797 Burns first degree Diseases 0.000 description 2
208000009043 Chemical Burns Diseases 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
206010062575 Muscle contracture Diseases 0.000 description 2
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
229940035674 anesthetics Drugs 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000004856 capillary permeability Effects 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
239000013043 chemical agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
238000011109 contamination Methods 0.000 description 2
208000006111 contracture Diseases 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
238000006345 epimerization reaction Methods 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000001473 noxious effect Effects 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000035939 shock Effects 0.000 description 2
229910001961 silver nitrate Inorganic materials 0.000 description 2
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
238000005670 sulfation reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
206010006803 Burns third degree Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
241001112696 Clostridia Species 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
206010069808 Electrical burn Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010020741 Hyperpyrexia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Chemical group CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
206010058119 Neurogenic shock Diseases 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010063562 Radiation skin injury Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000007234 antiinflammatory process Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000004500 asepsis Methods 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000004568 cement Substances 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
229940107200 chondroitin sulfates Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000001804 debridement Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
229940067232 ethanol 0.3 ml/ml medicated liquid soap Drugs 0.000 description 1
102000013373 fibrillar collagen Human genes 0.000 description 1
108060002894 fibrillar collagen Proteins 0.000 description 1
239000012458 free base Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
239000004519 grease Substances 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
229960004068 hexachlorophene Drugs 0.000 description 1
XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000003103 iduronosyl group Chemical group 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
GIKLTQKNOXNBNY-OWOJBTEDSA-N lewisite Chemical compound Cl\C=C\[As](Cl)Cl GIKLTQKNOXNBNY-OWOJBTEDSA-N 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
229960003640 mafenide Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000010422 painting Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000002488 pyknotic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
229940071536 silver acetate Drugs 0.000 description 1
YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
229910000367 silver sulfate Inorganic materials 0.000 description 1
LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000008149 soap solution Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
230000008961 swelling Effects 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AU78692/91A 1990-04-26 1991-04-25 Composition and method for topical treatment of damaged or diseased tissue Ceased AU647484B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US51350990A	1990-04-26	1990-04-26
US513509		1990-04-26
US68703491A	1991-04-22	1991-04-22
US687034		1991-04-22
PCT/US1991/002912 WO1991016058A1 (en)	1990-04-26	1991-04-25	Composition and method for topical treatment of damaged or diseased tissue

Publications (2)

Publication Number	Publication Date
AU7869291A AU7869291A (en)	1991-11-11
AU647484B2 true AU647484B2 (en)	1994-03-24

Family

ID=27057898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU78692/91A Ceased AU647484B2 (en)	1990-04-26	1991-04-25	Composition and method for topical treatment of damaged or diseased tissue

Country Status (10)

Country	Link
EP (1)	EP0526578A4 (ja)
JP (1)	JPH0776175B2 (ja)
CN (1)	CN1058341A (ja)
AU (1)	AU647484B2 (ja)
BR (1)	BR9106377A (ja)
CA (1)	CA2081340A1 (ja)
IE (1)	IE911403A1 (ja)
IL (1)	IL97976A0 (ja)
PT (1)	PT97504A (ja)
WO (1)	WO1991016058A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6153193A (en) *	1993-04-28	2000-11-28	Supratek Pharma Inc.	Compositions for targeting biological agents
US6093391A (en) *	1992-10-08	2000-07-25	Supratek Pharma, Inc.	Peptide copolymer compositions
US6277410B1 (en) *	1992-10-08	2001-08-21	Supratek Pharma Inc.	Copolymer compositions for oral delivery
US6353055B1 (en)	1994-11-18	2002-03-05	Supratek Pharma Inc.	Polynucleotide compositions
US6221959B1 (en)	1994-11-18	2001-04-24	Supratek Pharma, Inc.	Polynucleotide compositions
US6537977B1 (en) *	1995-09-19	2003-03-25	Seikagaku Corporation	Anti-inflammatory agent
JP2001187740A (ja) *	2000-01-05	2001-07-10	Seikagaku Kogyo Co Ltd	創傷治療剤
FR2833268B1 (fr) *	2001-12-12	2005-07-08	Fabre Pierre Dermo Cosmetique	Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
EP3677587A4 (en)	2016-08-31	2021-04-14	Oji Holdings Corporation	XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME
JP6225321B1 (ja)	2016-08-31	2017-11-08	王子ホールディングス株式会社	ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja)	2017-02-28	2018-02-21	王子ホールディングス株式会社	ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
CA3065747C (en)	2017-05-31	2024-10-01	Oji Holdings Corporation	MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE
PL3683242T3 (pl)	2017-09-12	2025-03-03	Oji Holdings Corporation	Polisiarczan pentozanu i sposób wytwarzania polisiarczanu pentozanu
KR102533822B1 (ko)	2017-12-20	2023-05-17	오지 홀딩스 가부시키가이샤	폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약
CN111228466B (zh) *	2020-02-27	2023-06-27	温州医科大学	治疗糖尿病足的含氧气微泡的水凝胶及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3997458A (en) *	1974-04-12	1976-12-14	Deknatel, Incorporated	Method of cleansing contaminated wounds and surgical scrub solutions for same
US4052513A (en) *	1974-12-13	1977-10-04	Plough, Inc.	Stable topical anesthetic compositions
IT1212892B (it) *	1983-10-11	1989-11-30	Della Valle Francesco	Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
US4745098A (en) *	1984-02-24	1988-05-17	The Regents Of The University Of California	Compositions and method for improving wound healing
US4711780A (en) *	1984-06-11	1987-12-08	Fahim Mostafa S	Composition and process for promoting epithelial regeneration
CH662505A5 (it) *	1985-04-30	1987-10-15	Seuref Ag	Composizioni farmaceutiche ad azione protettiva vascolare.
JPS61253065A (ja) *	1985-05-02	1986-11-10	片倉チツカリン株式会社	キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
FR2585575B1 (fr) *	1985-08-01	1989-03-03	Pf Medicament	Compositions pharmaceutiques a activite keratolytique sous forme de gel comportant de l'acide salicylique hydro-alcoolique
US4760131A (en) *	1986-04-23	1988-07-26	Collagen Corporation	Wound-healing composition
CA1294546C (en) *	1986-04-23	1992-01-21	John S. Sundsmo	Wound healing composition containing collagen
US4879109A (en) *	1986-05-15	1989-11-07	Emory University	Method for treating burns
NZ226171A (en) *	1987-09-18	1990-06-26	Ethicon Inc	Gel formulation containing polypeptide growth factor

1991
- 1991-04-25 CA CA002081340A patent/CA2081340A1/en not_active Abandoned
- 1991-04-25 WO PCT/US1991/002912 patent/WO1991016058A1/en not_active Ceased
- 1991-04-25 BR BR919106377A patent/BR9106377A/pt not_active Application Discontinuation
- 1991-04-25 EP EP19910909402 patent/EP0526578A4/en not_active Withdrawn
- 1991-04-25 IE IE140391A patent/IE911403A1/en unknown
- 1991-04-25 JP JP3509151A patent/JPH0776175B2/ja not_active Expired - Lifetime
- 1991-04-25 AU AU78692/91A patent/AU647484B2/en not_active Ceased
- 1991-04-26 PT PT97504A patent/PT97504A/pt not_active Application Discontinuation
- 1991-04-26 CN CN91103430A patent/CN1058341A/zh active Pending
- 1991-04-26 IL IL97976A patent/IL97976A0/xx unknown

Also Published As

Publication number	Publication date
PT97504A (pt)	1992-02-28
EP0526578A1 (en)	1993-02-10
IE911403A1 (en)	1991-11-06
CN1058341A (zh)	1992-02-05
WO1991016058A1 (en)	1991-10-31
AU7869291A (en)	1991-11-11
BR9106377A (pt)	1993-04-27
EP0526578A4 (en)	1993-09-22
JPH0776175B2 (ja)	1995-08-16
JPH05506861A (ja)	1993-10-07
IL97976A0 (en)	1992-06-21
CA2081340A1 (en)	1991-10-27

Publication	Publication Date	Title
AU647484B2 (en)	1994-03-24	Composition and method for topical treatment of damaged or diseased tissue
AU748516B2 (en)	2002-06-06	Topical drug preparations
US7902171B2 (en)	2011-03-08	Composition for treating inflammatory diseases
US20050214376A1 (en)	2005-09-29	Hydrogel-containing medical articles and methods of using and making the same
US9211305B2 (en)	2015-12-15	Pharmaceutical compositions with glycosaminoglycans and use thereof in the treatment of chronic ulcers
US5468737A (en)	1995-11-21	Wound healing accelerated by systemic administration of polysaccharide from aloe
CN119055562A (zh)	2024-12-03	一种宠物创伤天然护肤水凝胶及其制备方法和应用
CA2247198C (en)	2006-08-29	Topical pharmaceutical composition containing heparin
CN111214694B (zh)	2022-04-22	一种具有止血和加速伤口愈合功能的敷料及其制备方法
CN110198721B (zh)	2022-06-07	含有聚乙烯吡咯烷酮和二巯基丙磺酸钠的抗菌组合物及其用途
US20020037319A1 (en)	2002-03-28	Drug preparations
US20060233783A1 (en)	2006-10-19	Topical composition in the form of a gel for treating skin burns
CN113855849A (zh)	2021-12-31	一种敷料组合物及其制备方法和应用
EP1152723A1 (en)	2001-11-14	Enzymatic treatment and prevention of hypertrophic skin
CN110840894B (zh)	2020-06-02	一种复合抗疤痕硅酮喷雾剂及其制备方法
HK1208360A1 (en)	2016-03-04	Wound healing composition and uses thereof
WO2001039725A2 (en)	2001-06-07	Drug preparations
CA2069027A1 (en)	1992-11-25	Pharmaceutical composition for topical use for the healing and reepithelization of chronic phlebostatic ulcers
CN113855850A (zh)	2021-12-31	一种敷料组合物及其制备方法和应用
CN118949106A (zh)	2024-11-15	一种促进创面修复的多功能凝胶敷料及制备方法